Longitudinal brain volume measurement in multiple sclerosis: Rate of brain atrophy is independent of the disease subtype

Archives of Neurology

Volumn 59, Issue 10, 2002, Pages 1572-1576

  Kalkers, Nynke F ^a   Ameziane, Najim ^a   Bot, Joost C J ^a   Minneboo, Arjan ^a   Polman, Chris H ^a   Barkhof, Frederik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON;

ADULT; AGE; ARTICLE; AXONAL INJURY; BRAIN ATROPHY; BRAIN SIZE; BRAIN VENTRICLE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; FEMALE; FOLLOW UP; GENDER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; TISSUE INJURY;

ADULT; ANTHROPOMETRY; ATROPHY; BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 0036791829     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.59.10.1572     Document Type: Article

References (27)

1. van Walderveen MA, Barkhof F, Pouwels PJ, van Schijndel RA, Polman CH, Casteliins JA. Neuronal damage in Tl-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol. 1999;46:79-87.
2. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285.
3. Fu L, Matthews PM, Destefano N, et al. Imaging axonal damage of normalappearing white matter in multiple sclerosis. Brain. 1998;121(pt 1):103-113.
4. Simon JH. From enhancing lesions to brain atrophy in relapsing MS. J Neuroimmunol 1999;98:7-15.
5. Saindane AM, Ge Y, Udupa JK, Babb JS, Mannon LJ, Grossman RI. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS. Neurology. 2000;55:61-65.
6. Barnes D, McDonald WI, Landon DN, Johnson G. The characterization of experimental gliosis by quantitative nuclear magnetic resonance imaging. Brain. 1988;111(pt 1):83-94.
7. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRJ study. Brain. 1996;119(pt 6):2009-2019.
8. Kalkers NF, Bergers E, Castelijns JA, et al. Optimizing the association between disability and biological markers in MS. Neurology. 2001;57:1253-1258.
9. Fisher E, Rudick RA, Cutter GR, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler. 2000;6:373-377.
10. Rao SM, Glatt S, Hammeke TA, et al. Chronic progressive multiple sclerosis: relationship between cerebral ventricular size and neuropsychological impairment. Arch Neurol. 1985;42:678-682.
11. Huber SJ, Bornstein RA, Rammohan KW, Christy JA, Chakeres DW, McGhee RB. Magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 1992;4:152-158.
12. Edwards SG, Gong QY, Liu C, et al. Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis. Brain. 1999; 122(pt 2):291-301.
13. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L, for the Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology. 1999;53:1698-1704.
14. Simon JH, Jacobs LD, Campion MK, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology. 1999;53:139-148.
15. Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology. 2000;214:665-670.
16. Stevenson VL, Miller DH, Leary SM, et al. One-year follow-up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68:713-718.
17. Fox NC, Jenkins R, Leary SM, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology. 2000;54:807-812.
18. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907-911.
19. Kalkers NF, Bergers L, Castelijns JA, Polman CH, Barkhof F. Brain atrophy measurements in multiple sclerosis: Intra- and inter-observer reproducibility of 2 methods [abstract]. J Neurol. 2000; 247(suppl 1):111.
20. Rudick RA, Fisher E, Lee JC, Duda JT, Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler. 2000;6:365-372.
21. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology. 2000;54:813-817.
22. Sailer M, Losseff NA, Wang L, Gawne-Cain ML, Thompson AJ, Miller DH. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis: a prospective 18 months follow-up study. Eur J Neurol. 2001;8:37-42.
23. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain. 2000; 123(pt 11):2256-2263.
24. Brex PA, Jenkins R, Fox NC, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology. 2000;54:1689-1691.
25. Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology. 2001;56:1324-1330.
26. Hoogervorst ELJ, Kalkers NF, Uitdehaag BMJ, Polman CH. A study validating changes in the MS Functional Composite. Arch Neurol. 2002;59:113-116.
27. Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;70:773-780.